IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
FORMULATION, INVITRO AND INVIVO EVALUATION OF TASTE MASKED ORAL DISINTEGRATING TABLETS OF FAMOTIDINE

Author: NAGADANI. SWARNALATHA, VIDYAVATHI MARUVAJALA, KIRAN KUMAR
Abstract: The present research work was aimed at masking of the bitter taste of Famotidine and development of an orally disintegrating tablet (ODT) of the taste-masked drug by invitro and invivo evaluations in comparison with marketed tablets. In this present study, Eudragit EPO was used as the taste masking agent and sodium starch glycolate, crospovidone and croscarmellose sodium were used as superdisintegrants. Wet granulation method was used to prepare taste masked granules of Famotidine using different ratios of Famotidine and Eudragit EPO (1:1, 1:1.5, 1:2). The optimum ratio (1:2) of drug and Eudragit EPO was selected based on taste masking effect to prepare ODT of Famotidine using different percentages (3%, 6%, 9%) of three super disintegrants (FF1-FF9) by direct compression method. These were evaluated for thickness, weight variation, hardness, friability, disintegration time, wetting time, water absorption ratio, %drug content and invitro drug release. Then desirability function (DF) was calculated using disintegration time, t90% as significant parameters. The best formulation (FF9) showed highest DF value due to less disintegration time and 100% invitro drug release with in 10mins. Thus, FF9 was selected as the best among the prepared formulations to which stability studies were conducted. From the stability studies, it was confirmed that FF9 tablets are stable as there were no changes in the results of different parameters after storage at 40º±2ºC and RH 75%±5% for 3 months in a stability chamber. Invivo studies were performed on rabbits with the best selected formulation to find Cmax, tmax, AUC, Kel and t1/2. The total bioavailability (AUC0-24 and AUC0-a) was increased for test formulation compared to reference formulation (Fluxid). From the results of invivo pharmacokinetic studies, it was concluded that, Famotidine was successfully prepared as ODT with increased AUC and decreased tmax than marketed formulation.
Keyword: HPLC, Famotidine, Ranitidine, Internal standard. INTRODUCTION During the last decade, oral disintegrating tablets have received ever more demand [1]. Drugs that are showing great absorption from oral mucosa and are intended for instant pharmacological action are well suitable to formulate into ODT [2]. Difficulties in swallowing of tablet and pill also occur while water isn't available, in diarrhoea, cough, allergic condition and bronchial contamination [3]. About third of the population (in particular pediatric and geriatric) has swallowing difficulties, resulting in to poor compliance with oral pill drug remedy which leads to reduced average remedy effectiveness. For those motives, tablets that can swiftly dissolve or disintegrate within the oral cavity have attracted an extremely good deal of attention due to avoiding of swallowing difficulties. Maximum oral disintegrating tablets should include substances to mask the bitter taste of the active ingredient. The taste masked active ingredient can be easily swallowed by saliva along with the soluble and insoluble excipients [4, 5]. As it will be a soft paste or liquid form, and thus it becomes
DOI: https://doi.org/10.31838/ijpr/2019.11.02.047
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477